Approaches to implement bispecific antibody treatment of ovarian carcinoma.
Canevari
S
S
Division of Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy.
Mezzanzanica
D
D
Mazzoni
A
A
Negri
D R
DR
Figini
M
M
Ramakrishna
V
V
Bolis
G
G
Colnaghi
M I
MI
D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D018106:CD28 Antigens / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D005260:Female; D058973:Folate Receptors, GPI-Anchored; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008213:Lymphocyte Activation / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D011956:Receptors, Cell Surface; D013601:T-Lymphocytes / Q000276:immunology
D018033:Antibodies, Bispecific; D018106:CD28 Antigens; D017252:CD3 Complex; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D011956:Receptors, Cell Surface